Alice C.

“To find satisfaction in striving towards a collective purpose, to face the challenges of scientific innovation for improving (and saving) lives of fellow human beings.“ — Alice C.

Continue ReadingAlice C.
Read more about the article @AllogeneTx: Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

@AllogeneTx: Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about…

Continue Reading@AllogeneTx: Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021

Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021

Continue ReadingAllogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021
Read more about the article @AllogeneTx: Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

@AllogeneTx: Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about…

Continue Reading@AllogeneTx: Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO
Read more about the article Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about…

Continue ReadingToday we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO
Read more about the article @AllogeneTx: Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang, we're proud of the rich legacies our co-founders and advisors bring to Allogene and oncology!

@AllogeneTx: Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang, we're proud of the rich legacies our co-founders and advisors bring to Allogene and oncology!

Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang,…

Continue Reading@AllogeneTx: Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang, we're proud of the rich legacies our co-founders and advisors bring to Allogene and oncology!
Read more about the article @AllogeneTx: Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang, we’re proud of the rich legacies our co-founders and advisors bring to Allogene and oncology!

@AllogeneTx: Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang, we’re proud of the rich legacies our co-founders and advisors bring to Allogene and oncology!

Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang,…

Continue Reading@AllogeneTx: Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang, we’re proud of the rich legacies our co-founders and advisors bring to Allogene and oncology!